Cytek Biosciences, Inc.
CTKB
$3.65
-$0.02-0.55%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 200.45M | 201.21M | 197.71M | 200.79M | 193.01M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 200.45M | 201.21M | 197.71M | 200.79M | 193.01M |
| Cost of Revenue | 89.35M | 90.71M | 89.04M | 89.39M | 83.59M |
| Gross Profit | 111.11M | 110.50M | 108.68M | 111.40M | 109.43M |
| SG&A Expenses | 94.83M | 93.60M | 92.66M | 93.85M | 93.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 223.58M | 224.86M | 223.53M | 227.20M | 220.86M |
| Operating Income | -23.12M | -23.65M | -25.82M | -26.42M | -27.85M |
| Income Before Tax | -5.70M | -11.91M | -16.25M | -15.66M | -15.71M |
| Income Tax Expenses | 320.00K | -1.75M | 1.30M | -4.15M | -3.56M |
| Earnings from Continuing Operations | -6.02 | -10.16 | -17.56 | -11.51 | -12.15 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.02M | -10.16M | -17.56M | -11.51M | -12.15M |
| EBIT | -23.12M | -23.65M | -25.82M | -26.42M | -27.85M |
| EBITDA | -15.91M | -16.66M | -18.91M | -19.67M | -21.80M |
| EPS Basic | -0.04 | -0.08 | -0.13 | -0.09 | -0.09 |
| Normalized Basic EPS | -0.04 | -0.06 | -0.08 | -0.07 | -0.07 |
| EPS Diluted | -0.05 | -0.08 | -0.14 | -0.09 | -0.09 |
| Normalized Diluted EPS | -0.04 | -0.06 | -0.08 | -0.07 | -0.07 |
| Average Basic Shares Outstanding | 522.45M | 526.91M | 532.08M | 536.56M | 541.12M |
| Average Diluted Shares Outstanding | 524.23M | 528.69M | 532.08M | 536.56M | 541.12M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |